Interleukin-33 and Obesity-Related inflammation and Cancer
Preprint
- 3 September 2024
- preprint
- Published by MDPI AG in Preprints.org
Abstract
Obesity and chronic inflammation are well-known risk factors for cancer. Interleukin-33 (IL-33) functions in inflammatory diseases, particularly those related to obesity and cancer. However, the correlation and molecular mechanisms linking IL-33, obesity, and cancer remain unclear. IL-33 is a nuclear cytokine released as an alarm signal when cells are damaged or stressed. It is expressed in epithelial, endothelial, and fibroblast-like cells during normal conditions and in-flammation. When IL-33 is present, immune cells expressing the IL-1RL1/ST2 receptor are alerted in response to tissue damage or cell injury. Research on IL-33 and its correlation with obesity has revealed improvements in inflammatory and metabolic changes associated with obesity. IL-33 can have both pro-tumorigenic and antitumorigenic effects, depending on the cellular content, in-flammatory environment, expression levels, and bioactivity of IL-33. This review will discuss the various functions of IL-33 in obesity-driven inflammation and cancers and how they intersect.Keywords
All Related Versions
- Version 1, 2024-09-03, Preprints
- Published version: Encyclopedia, 4 (4), 1770.
This publication has 126 references indexed in Scilit:
- Mast Cells and Resistance to Immunotherapy in CancerArchivum Immunologiae et Therapiae Experimentalis, 2023
- Interleukin (IL)‐33: an orchestrator of immunity from host defence to tissue homeostasisClinical & Translational Immunology, 2020
- Activated M2 Macrophages Contribute to the Pathogenesis of IgG4‐Related Disease via Toll‐like Receptor 7/Interleukin‐33 SignalingArthritis & Rheumatology, 2019
- IL-33 in obesity: where do we go from here?Inflammation Research, 2019
- Interleukin-33 in tumorigenesis, tumor immune evasion, and cancer immunotherapyJournal of Molecular Medicine, 2016
- Interleukin‐4 receptor alpha overexpression in human bladder cancer correlates with the pathological grade and stage of the diseaseCancer Medicine, 2014
- IgE and IL‐33−mediated triggering of human basophils inhibits TLR4−induced monocyte activationEuropean Journal of Immunology, 2014
- The paracrine effect of cancer‐associated fibroblast‐induced interleukin‐33 regulates the invasiveness of head and neck squamous cell carcinomaThe Journal of Pathology, 2013
- IL‐33 synergizes with TCR and IL‐12 signaling to promote the effector function of CD8+ T cellsEuropean Journal of Immunology, 2011
- The pro‐Th2 cytokine IL‐33 directly interacts with invariant NKT and NK cells to induce IFN‐γ productionEuropean Journal of Immunology, 2009